Acalabrutinib Triplet Highly Active in Frontline CLL

The triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva; AVO) is highly active as frontline therapy for patients with chronic lymphocytic leukemia.

Read the full article here

Related Articles